Published in N Engl J Med on January 20, 2010
Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis (PRAG-MS) | NCT03345940
Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain (2012) 5.83
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov (2010) 5.55
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol (2012) 2.79
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 2.55
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology (2012) 2.54
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A (2010) 2.49
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology (2014) 2.41
The human plasma lipidome. N Engl J Med (2011) 2.35
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology (2012) 2.30
Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice. J Clin Invest (2011) 2.23
International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev (2010) 2.10
Fingolimod after natalizumab and the risk of short-term relapse. Neurology (2014) 1.96
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol (2015) 1.88
An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol (2010) 1.87
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry (2015) 1.80
Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med (2010) 1.73
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med (2012) 1.68
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med (2011) 1.65
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology (2015) 1.65
Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology (2012) 1.65
Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol (2010) 1.62
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry (2014) 1.61
Fingolimod modulates peripheral effector and regulatory T cells in MS patients. J Neuroimmune Pharmacol (2013) 1.59
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother (2011) 1.58
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. Neurology (2015) 1.55
Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci (2013) 1.52
Multiple sclerosis-a quiet revolution. Nat Rev Neurol (2015) 1.47
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol (2013) 1.47
Nogo-B regulates endothelial sphingolipid homeostasis to control vascular function and blood pressure. Nat Med (2015) 1.46
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2011) 1.46
Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ). J Med Internet Res (2011) 1.39
An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res (2014) 1.37
Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol (2010) 1.36
Sphingosine 1-phosphate in coagulation and inflammation. Semin Immunopathol (2011) 1.34
Multiple sclerosis review. P T (2012) 1.34
Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord (2012) 1.31
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol (2012) 1.30
Sphingosine-1-phosphate and immune regulation: trafficking and beyond. Trends Pharmacol Sci (2010) 1.27
Novel targeted therapies for mantle cell lymphoma. Oncotarget (2012) 1.27
Oral therapy for multiple sclerosis--sea change or incremental step? N Engl J Med (2010) 1.25
N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis. J Biol Chem (2011) 1.21
Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma. Neuro Oncol (2012) 1.21
Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta (2012) 1.21
The role of sphingosine-1-phosphate transporter Spns2 in immune system function. J Immunol (2012) 1.20
What's fueling the biotech engine--2010 to 2011. Nat Biotechnol (2011) 1.17
The adaptive immune system in diseases of the central nervous system. J Clin Invest (2012) 1.17
Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol (2013) 1.16
Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol (2011) 1.15
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol (2014) 1.14
Sphingosine 1-phosphate signalling. Development (2014) 1.14
Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology (2015) 1.12
Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci (2012) 1.09
Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord (2010) 1.08
Vision and vision-related outcome measures in multiple sclerosis. Brain (2014) 1.08
Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology (2011) 1.07
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol (2013) 1.06
Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis. Neurology (2015) 1.05
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther (2014) 1.05
Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol (2013) 1.05
A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res (2011) 1.05
Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol (2013) 1.04
Defining and scoring response to IFN-β in multiple sclerosis. Nat Rev Neurol (2013) 1.04
Treatment of cognitive impairment in multiple sclerosis: position paper. J Neurol (2012) 1.04
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol (2011) 1.03
Lymphocyte modulation with FTY720 improves hemorrhagic shock survival in swine. PLoS One (2012) 1.03
Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors. Bioorg Med Chem (2011) 1.03
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. PLoS One (2012) 1.02
S1P is associated with protection in human and experimental cerebral malaria. Mol Med (2011) 1.02
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology (2015) 1.01
Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord (2010) 1.01
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler (2015) 1.00
Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol (2014) 1.00
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol (2014) 0.98
Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol (2011) 0.98
Targeting cells in motion: migrating toward improved therapies. Eur J Immunol (2013) 0.98
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol (2013) 0.98
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci (2015) 0.98
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord (2015) 0.97
FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl. Eur Respir J (2010) 0.97
Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug Healthc Patient Saf (2013) 0.97
Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol (2011) 0.97
Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS One (2014) 0.96
Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders. Surv Ophthalmol (2013) 0.96
Fingolimod for the treatment of neurological diseases-state of play and future perspectives. Front Cell Neurosci (2014) 0.96
Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence (2011) 0.96
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis. Case Rep Med (2012) 0.95
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood (2011) 0.95
Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clin Exp Immunol (2014) 0.95
Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort. J Neurol (2013) 0.95
Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol (2011) 0.94
Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study. Mult Scler Int (2015) 0.94
An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations. Patient Prefer Adherence (2015) 0.94
Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients. Interact J Med Res (2015) 0.94
The sphingosine 1-phosphate receptor, S1PR₁, plays a prominent but not exclusive role in enhancing the excitability of sensory neurons. J Neurophysiol (2010) 0.94
Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models. J Neuroimmunol (2014) 0.93
Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol (2011) 0.93
Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America. Ther Adv Neurol Disord (2011) 0.92
Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. Br J Pharmacol (2012) 0.92
Topical application of FTY720 and cyclosporin A prolong corneal graft survival in mice. Mol Vis (2012) 0.92
New approaches in the management of multiple sclerosis. Drug Des Devel Ther (2010) 0.92
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 7.58
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Guillain-Barré syndrome. N Engl J Med (2012) 6.28
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov (2010) 5.55
Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature (2003) 5.31
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan: Response. Radiology (2017) 4.99
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med (2010) 4.08
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med (2013) 4.02
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet (2009) 3.92
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Acute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol (2007) 3.81
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59
Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature (2005) 3.53
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol (2010) 3.26
Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet (2003) 3.22
Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med (2012) 3.16
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet (2006) 3.13
No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Ann Neurol (2011) 3.07
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol (2010) 3.05
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet (2013) 2.89
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol (2012) 2.68
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol (2009) 2.56
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology (2005) 2.47
Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 2.45
Evidence for acute neurotoxicity after chemotherapy. Ann Neurol (2010) 2.45
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology (2014) 2.41
Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis (2010) 2.32
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci (2002) 2.21
Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol (2009) 2.20
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain (2010) 2.19
Long-term outcomes of CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) in a consecutive series of 12 patients. Arch Neurol (2012) 2.13
Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One (2010) 2.12
Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler (2005) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol (2007) 2.07
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07